GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal.

LONDON - GSK plc (LSE/NYSE:GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

Efimosfermin is described as a phase III-ready, investigational specialty medicine intended for the treatment and prevention of progression of steatotic liver disease (SLD), including metabolic ...

Efimosfermin is a phase III-ready investigational treatment for steatotic liver disease (SLD), specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...

Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.” GSK indicated that the addition of efimosfermin expands its pipeline for ...